Early Results Show Nasal Spray Reduced Risk of Severe COVID by 86%

A nasal vaccine that could finally curb Covid infections is one step closer to a reality after promising early trial results.

The inhaled vaccine, made by researchers in Georgia, successfully reduced the risk of symptomatic Covid infections by 86 percent for three months in people who received it as a booster – almost double the protection the mRNA boosters provide.

While still in early stages, it is an exciting development that could prove more effective than the booster doses administered as injections.

The nasal, or ‘mucosal’ vaccines are appealing for their ability to prime immune cells in the mucous membranes that line the nostril cavities and the mouth where the coronavirus first enters the body, and stop the virus in its tracks.

Click Here to Read More.


The Mail

Related Articles

Back to top button